Heat shock cognate protein 70 encodes antigenic epitopes recognised by HLA-B4601-restricted cytotoxic T lymphocytes from cancer patients by Azuma, K et al.
Heat shock cognate protein 70 encodes antigenic epitopes
recognised by HLA-B4601-restricted cytotoxic T lymphocytes
from cancer patients
K Azuma
1, S Shichijo*,1, H Takedatsu
1, N Komatsu
1, H Sawamizu
1 and K Itoh
1
1Department of Immunology, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka 830-0011, Japan
Heat shock cognate protein 70 (HSC70), a highly conserved protein and a member of the family of molecular chaperones, has the
ability to induce cytotoxic T lymphocyte (CTL) responses through binding and carrying antigenic peptides. We demonstrated in this
study that the HSC70 gene encodes two antigenic peptides recognised by HLA-B46-restricted and tumour-reactive CTLs established
from tumour-infiltrating lymphocytes of a colon cancer. These HSC70-derived peptides, at amino-acid positions 106–114 and 233–
241, had the ability to induce HLA-B46-restricted and peptide-specific CTLs, which are reactive to tumour cells, from peripheral
blood mononuclear cells of the majority of epithelial cancer patients tested. These results, along with those from the previous studies,
indicate the two ways of HSC70 involvement in the immune responses to tumours: chaperones and antigens, and thus may provide a
new insight for the development of HSC70-directed cancer-specific immunotherapy.
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Current modalities for cancer immunotherapy are rarely con-
sidered from the viewpoint of adaptive immunity. Therefore, the
development of a new modality directed by adaptive immunity is
needed. Many antigenic peptides recognised by HLA-A class I
restricted cytotoxic T lymphocytes (CTLs) were identified during
the past decade (van der Bruggen et al, 1991; Kawakami et al, 1994;
Boon and van der Bruggen, 1996; Shichijo et al, 1998; Yang et al,
1999; Azuma et al, 2003), and several clinical trials using these
antigenic peptides have been carried out (Wang et al, 1999; Jager
et al, 2000; Gohara et al, 2002). However, tumour regression was
rarely observed in such clinical studies, and the molecular basis of
immunotherapy for cancer remains to be fully elucidated. One
potential approach for better understanding of molecular basis of
tumour immunology could be to identify antigenic peptides
recognised by HLA-B class I-restricted CTLs. We recently
established HLA-B4601-restricted and tumour-reactive CTL line
from T lymphocytes infiltrating into colon tumours (Azuma et al,
2003). HLA-B4601 allele is exclusively expressed in Asians, and
there is no such study except for our previous report. Subse-
quently, with that CTL line, we extended our study to identify
antigenic epitopes capable of binding to HLA-B4601 allele; we
report in this study that heat shock cognate protein 70 (HSC70)
gene encodes two nonmutated nonapeptides with the ability to
induce HLA-B4601-restricted and tumour-reactive CTLs from
cancer patients. HSC70 was reported to elicit protective immunity
to a diverse array of cancers mainly through binding and carrying
of tumour-derived epitopes to CTLs (Blachere et al, 1997; Udono
et al, 2001). We discussed in this study the possible contribution of
the HSC70-derived peptides by themselves in induction of tumour-
reactive CTLs.
MATERIALS AND METHODS
Tumour cell lines
The epithelial cancer cell lines used in this study were OSC20
(HLA-B46
þ, oral cancer), Ca9-22 (HLA-B46
þ, oral cancer),
MKN45 (HLA-B46
þ, stomach cancer), Kuma-1 (HLA-B46
 , head
and neck cancer), SW620 (HLA-B46
 , colon cancer), COLO320
(HLA-B46
 , colon cancer), KWS (HLA-B46
 , stomach cancer),
COS-7 (SV40 transformed African Green monkey kidney cell), and
Epstein–Barr virus (EBV)-transformed B cell line (EBV-B
3) (HLA-
B46
þ) established from peripheral blood mononuclear cells
(PBMCs) of a colon cancer patient from whom the OKB-CTL line
was established. Details of these cell lines were reported elsewhere
(Azuma et al, 2003).
Identification of the cDNA clone
The HLA-B46-restricted and tumour cell-reactive CTL (OKB-CTL)
line was established from tumour-infiltrating lymphocytes (TILs)
of a patient with colon cancer (HLA-A0207/3101,  B4601/5101,
 Cw1) by incubation with interleukin-2 (IL-2) (100Uml
 1) alone
for more than 50 days by the methods as reported previously (Ito
et al, 2001). The surface phenotypes of the CTLs were investigated
by immunofluorescence assay with anti-CD3, -CD4, -CD8, anti-
CD16 (Nichirei, Tokyo, Japan), and anti-NkD2D (R&D Systems,
Inc, Mckinley, NE, USA) monoclonal antibodies (mAbs) with
FACScan as reported previously (Azuma et al, 2003). Received 18 March 2003; revised 16 June 2003; accepted 24 June 2003
*Correspondence: Dr S Shichijo; E-mail: shichijo@med.kurume-u.ac.jp
British Journal of Cancer (2003) 89, 1079–1085
& 2003 Cancer Research UK All rights reserved 0007– 0920/03 $25.00
www.bjcancer.com
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
yThe cDNA expression gene cloning method, described pre-
viously (Shichijo et al, 1998), was used to identify genes coding for
tumour antigens recognised by the OKB-CTL. In brief, poly (A)
þ
RNA of the SW620 tumour cells was converted to cDNA, ligated to
the SalI adapter, and inserted into the expression vector pCMV-
SPORT-2 (Invitrogen, San Diego, CA, USA). cDNAs of HLA-B4601,
-B5201, -B5101, and -A0207 were obtained by reverse transcription
(RT)–polymerase chain reaction (PCR) and cloned into the
eukaryotic expression vector pCR3 (Invitrogen). A measure of
200ng of the plasmid DNA pools as well as the clones of the SW620
cDNA library were mixed with 200ng of the HLA-B4601 cDNA in
120ml of OPTI-MEM (Invitrogen) for 30min. A 50ml aliquot of the
mixture was then added to the COS-7 cells (5 10
3), followed by
incubation for 5h. RPMI-1640 medium containing 10% foetal calf
serum (FCS) was then added and cultured for 2 days followed by
addition of the OKB-CTLs (5 10
4 cells per well). After an 18-h
incubation, 100ml of supernatant was collected and tested for the
production of interferon-g (IFN-g) by enzyme-linked immuno-
sorbent assay (ELISA) in a duplicate assay. DNA sequencing of a
positive cDNA clone was performed with a dideoxynucleotide
sequencing method using a DNA Sequencing kit (Perkin-Elmer,
Foster, CA, USA) and analysed by an ABI PRISMt 377 DNA
Sequencer (Perkin-Elmer).
Northern and Western blot analyses
Preparation of the RNA (5mg per lane), the transfer of RNA to
nylon membranes, and the subsequent hybridisation processes
have been described elsewhere (Shichijo et al, 1998). A
32P-labelled
704bp fragment of AccI-digested HSC70 cDNA was used as a
probe, which has 74% homology with the stress-inducible heat
shock protein 70 (HSP70) at the nucleotide level. The membranes
were washed four times and then autoradiographed. The expres-
sions of HSC70 and HSP70 were investigated at the protein level by
means of Western blotting with anti-Hsc70 (Product#:SPA-815,
Stressgen, Victoria, Canada) and anti-Hsp70 (Product#:SPA-810,
Stressgen) mAbs, respectively. HSP70 is a family of HSPs, and has
74 and 81% sequence homology with HSC70 at the nucleotide and
amino-acid levels, respectively. The method for Western blotting
was reported elsewhere (Yang et al, 1999).
Peptides and CTL assay
Peptides capable of binding to the HLA-B4601molecules were
sought in the literature with regard to peptides for HLA-B4601-
binding motifs (third amino acids (aa) were K, R, N, I, P, and F,
and ninth aa were Y or F) (Barber et al, 1996), and the following 10
different peptides (470% purity) were synthesised for screening
(HSC7033–41, HSC7059–67, HSC7069–77, HSC70106–114, HSC70136–
144, HSC70233–241, HSC70237–245, HSC70346–354, HSC70451–459, and
HSC70537–545). For further studies, two peptides (HSC70106–114
and HSC70233–241 with 490% purity) were obtained. For the
detection of antigenic peptides, COS-7 (5 10
3) cells transfected
with the HLA-B4601, HLA-B5101,o rHLA-B5201 cDNA were
pulsed with each of 20 peptides at five different concentrations for
2h, and then incubated with CTLs for 18h. The supernatants were
collected to measure IFN-g by ELISA (limit of sensitivity:
10pgml
 1) in a duplicate assay.
Cytotoxic T lymphocyte induction from cancer patients
Peripheral blood mononuclear cells from 80 epithelial cancer
patients (40 non-small-cell lung cancer patients, 30 prostate cancer
patients, and 10 colon cancer patients) and also from 40 HDs were
provided for screening of serological expression of HLA-B types.
Subsequently, PBMCs from 10 HLA-B46
þ cancer patients (five
lung cancer and five prostate cancer patients) and four HLA-B46
þ
HD served as subjects for the CTL induction assay. Informed
consent was obtained from all subjects. The HLA-class I of PBMCs
was serotyped by conventional serological methods, as reported
previously (Yang et al, 1999). The HLA-B alleles were also
genotyped by the methods as reported previously (Azuma et al,
2003), and all of them were B4601, which was expected since the
genotype of B46 in Asians is predominantly (495%) a B4601
(Imanishi et al, 1992; Barber et al, 1996; Akesaka et al, 2000). For
the induction of peptide-specific CTLs, PBMCs (1 10
5 cells per
well) were incubated with 10mM of each peptide in a round-bottom
96-well microculture plate (Nunc, Roskilde, Denmark) in 200ml
culture medium containing IL-2, as reported previously (Maeda
et al, 2002). On the fourth and seventh days of culture, half of the
medium was replaced with a new medium containing a
corresponding peptide. On the 10th day, the cells were harvested,
washed, and tested in duplicate assays for their ability to produce
IFN-g in response to HLA-B4601-transfected COS-7 cells pulsed
with a corresponding peptide or a negative control peptide, which
can bind to HLA-B4601molecules (p53204–212) (Azuma et al,
2003). The peptide-stimulated PBMCs were further incubated for
more than 10 days, and their cytotoxicity against OSC20 (HLA-
B46
þ) tumour cells, Kuma-1 (HLA-B46
 ) tumour cells, and PHA-
blastoid T cells (HLA-B46
þ) was tested by a standard 6-h
51Cr-
release assay, as reported previously (Azuma et al, 2003). To
inhibit CTL activity, 20mgml
 1 of anti-HLA-class I (W6/32,
IgG2a), anti-CD4 (Nu-Th/i, IgG1), anti-HLA-B, C (B1-23, IgG2a),
anti-CD8 (Nu-Ts/c, IgG2a), and anti-HLA-class II (H-DR-1, IgG2a)
mAbs were used (Azuma et al, 2003). Anti-CD14 (JML-H14, IgG2a)
mAb served as a negative control. For the cold target inhibition
assay, unlabeled cells of HLA-B46
þ EBV-B cells were incubated
with a corresponding or a control peptide for 2h, washed, and
added to the
51Cr-labelled targets at a cold:hot target ratio of 20:1.
Two-tailed Student’s t-test was employed for the statistical analysis
for this entire study.
RESULTS
Identification of the gene and its expression
HLA-B46-restricted and tumour-reactive CTLs (OKB-CTLs) were
used for cDNA screening to clone genes. Although the details
regarding the characteristics of the OKB-CTLs were reported
elsewhere (Azuma et al, 2003), we have tested the expression of
CTL (CD3 and CD8) and NK cell markers (CD16 and NKD2D) on
OKB-CTLs that were used as indicator cells for cloning of genes in
this study, to exclude possible involvement of NK cell-mediated
recognition of target cells. The surface phenotypes of the OKB-
CTLs were CD3
þ (498%) CD8
þ(490%) CD4
  (o5%) CD16
 
(o1%) NKD2D
  (o1%). The results suggest no involvement of
NK cell-mediated recognition of target cells in the case of the OKB-
CTLs used in this study.
A total of 1 10
5 cDNA clones from the cDNA library of SW620
tumour cells and HLA-B4601 cDNA were cotransfected to the COS-
7 cells followed by a test of their ability to stimulate IFN-g
production by the OKB-CTLs. After repeated experiments, one
cDNA clone, 3H, was identified. Representative results from the
three different experiments are shown in Figure 1A. The sequence
of 3H proved to be 2218 base pairs (bp), and it was almost identical
to that of the stress-inducible HSPA8 (HSC70), although it was
36bp shorter at the 50-end and 6bp shorter at the 30-end than the
registered sequence of HSPA8 (Accession No.: NM 006597).
Neither mutation nor polymorphism was found in the sequence.
Its open reading frame started from 43 to 1980bp. It encodes 641
aa’s and has 81% of homology at the aa levels with the stress-
inducible heat shock protein 70 (HSA70) with 646 aa’s.
The OKB-CTLs recognised COS-7 cells cotransfected with the
clone 3H gene and the HLA-B4601 gene in a dose-dependent
fashion. The results of three separate experiments are shown in
HSC70 recognised by HLA-B46-restricted CTLs
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yFigure 1A. In contrast, the OKB-CTLs failed to recognise COS-7
cells cotransfected with the clone 3H and the HLA-B5201, -B5101,
or the HLA-A0207 gene. The OKB-CTLs also failed to recognise
COS-7 cells transfected with either the HLA-B4601 gene or clone
3H alone (data not shown). The mRNA expression of clone 3H in
various tumour cells and normal cells was analysed by Northern
blotting, and the representative result is shown in Figure 1B. It was
highly expressed in Ca9-22, SW620, OSC20, Kuma-1, and MKN45
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Figure 1 Determination of the gene. (A) Identification of a gene coding for tumour antigen. Amounts of 100ng of a clone 3H from SW620 cDNA
libraries and 100ng of the HLA-B4601 gene were cotransfected into COS-7 cells. The HLA-B5101 or HLA-B5201 gene was used as a negative control. After
incubation for 48h, the cells were tested for their ability to stimulate IFN-g production by the OKB-CTLs. COS-7 cells transfected with HLA-A0207 and
clone 3H were also served as a negative control. The results of three separate experiments are shown in the figure. The background IFN-g production in
response to COS-7 cells (o100pgml
 1) was subtracted. The values represent means of triplicate assays. *Po0.05 by a two-tailed Student’s t-test. (B) The
mRNA expression of HSC70. The mRNA expression of HSC70 in various tumour cells and normal cells was analysed by Northern blotting. Representative
results are given in the figure. (C) The expression levels of the constitutively expressed HSC70 or the stress-inducible HSP70 in the samples used for
Northern blotting were investigated at the protein level by means of Western blotting with anti-Hsc70 or -Hsp70mAb, respectively, to further investigate
the expression of HSP family in tumour cells. (D) Recognition of an HSC70-derived peptide by the OKB-CTLs. Various doses of the peptides were loaded
onto HLA-B4601-transfected COS-7 cells for 2h followed by addition of the OKB-CTLs at an E/T ratio of 10:1. After 18h incubation, the culture
supernatants were collected in order to measure the IFN-g production. The values represent of means of duplicate assays.
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þ tumour cells were susceptible to lysis by
the OKB-CTLs, as reported elsewhere (Azuma et al, 2003). In
contrast, it was moderately expressed in KWS and COLO320, and
weakly expressed in PHA-blastoid T cells and PBMCs. HLA-B46
þ
PHA-blastoid T cells were not lysed by the OKB-CTLs as reported
previously (Azuma et al, 2003).
The expression levels of the constitutively expressed HSC70 or
the stress-inducible HSP70 in the samples used for Northern
blotting were investigated at the protein level by means of Western
blotting with anti-Hsc70 or -Hsp70mAb, respectively, to further
investigate the expression of HSP family in tumour cells. HSP70 is
a family of HSPs, and has 74 and 81% sequence homology with
HSC70 at the nucleotide and aa levels, respectively. Expression
levels of HSC70 in all the tumour cells and PHA-blast were higher
than that in PBMCs, while those of HSP70 in all the tumour cells
were higher than that in PHA-blast, which in turn was higher than
that of PBMCs (Figure 1C).
Identification of CTL-directed epitopes
To identify the CTL-directed epitopes of HSC70, 10 kinds of
HSC70-derived nonapeptides with HLA-B46-binding motifs were
loaded on COS-7 cells transfected with HLA-B4601 or HLA-B5201
gene as a negative control, and then were tested for their ability to
stimulate IFN-g production by the OKB-CTLs. Two peptides,
HSC70106–114 and HSC70233–241, were recognised by the OKB-
CTLs in a dose-dependent fashion, and the highest IFN-g
production was observed at the concentration of 1mM peptide
(Figure 1D). These two peptides were then tested for their ability to
induce HLA-B46-restricted and tumour-reactive CTLs from the
PBMCs of 10 HLA-B46
þ cancer patients and 4 HD (Figure 2A).
Higher levels of IFN-g production (4100pgml
 1) by recognition
of the corresponding peptide were observed in the following cases:
HSC70106–114 peptide-stimulated PBMCs from six of 10 cancer
patients and two of four HD; and HSC70233–241 peptide-stimulated
PBMCs from three of 10 cancer patients and zero of four HD
(Figure 2A). All of these PBMCs from cancer patients, but not from
those of any HDs, also produced higher levels of IFN-g production
(4100pgml
 1) in response to OSC20 cells (HLA-B46
þHSC70
þ)
but not in response to Kuma-1 cells (HLA-B46
 HSC70
þ)
(Figure 2A). The background IFN-g production in response to
the Kuma-1 tumour cells (o50pgml
 1) was subtracted in the
Figure 2A. Then, the cytotoxicity of the peptide-stimulated PBMCs
from six cancer patients and those from two HDs was confirmed
by a 6-h
51Cr-release assay, and the representative results of cancer
patients were shown in Figure 2B. The PBMCs stimulated by the
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Figure 2 Determination of CTL epitope peptides. (A) Two peptides, HSC70106–114 and HSC70233–241, were tested for their ability to induce HLA-B46-
restricted and tumour-reactive CTLs from the PBMCs of HLA-B46
þ 10 cancer patients and four HDs. The details of the method are described in the
Materials and Methods section. The data showed amounts of IFN-g produced by peptide-treated PBMC in response to HLA-B4601-transfected COS7 cells
pulsed with the corresponding peptides (left column) and OSC20 (HLA-B46
þ) tumour cells (right column) at an E/T ratio of 20:1. The background IFN-g
release in response to HLA-B4601-transfected COS7 cells pulsed with a control peptide (p53204–212)( o100pgml
 1) was subtracted. The background
IFN-g release in response to Kuma-1 (HLA-B46) tumour cells (o50pgml
 1) was also subtracted from the figure. The values represent the means of
duplicate assays. (B) The cytotoxicity of the peptide-treated PBMCs from seven cancer patients against OSC20 (HLA-B46
þ), Kuma-1 (HLA-B46
 ), and
PHA-blastoid T cells was confirmed by a 6-h
51Cr-release assay. Values represent the means of triplicate assays at three different E/T ratios. *Po0.05 by a
two-tailed Student’s t-test.
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cytotoxicity against the OSC20 cells, no or low levels of cytotoxicity
against Kuma-1 cells, and no cytotoxicity against PHA-blastoid T
cells (HLA-B46
þ) (Figure 2B). The peptide-stimulated PBMCs
from a few cases (#1–#3) showed the low levels of cytotoxicity (5–
10%) against Kuma-1 tumour cells at the higher effector to target
(E/T) ratio, but it would be largely due to the cytotoxicity mediated
by lymphokine-activated killer cells. In contrast, the HLA-
restricted cytotoxicity against tumour cells was not obtained from
the HSC70106–114 peptide-stimulated PBMCs from HD3 and HD4.
Collectively, PBMCs from the majority (six of 10 cases) of cancer
patients but none from HDs tested showed HLA-B46-restricted
cytotoxicity against tumour cells after in vitro stimulation by at
least one of these two peptides. Peripheral blood mononuclear cells
activated with IL-2 alone without peptide stimulation from these
patients did not show such cytotoxicity (data not shown).
Cytotoxic T lymphocytes activity of the PBMCs stimulated with
the HSC70106–114 and HSC70233–241 peptides was inhibited by anti-
CD8, anti-HLA-B, C, and anti-HLA class I mAb but not by any
other mAbs tested. Representative results of two cases are given in
Figure 3A. Their cytotoxicity against OSC20 tumour cells was also
inhibited by anti-CD8, anti-HLA class I, or anti-HLA-B, C mAb,
but not by any other mAbs tested. Representative results of Pt. 2
were shown in Figure 3B. Peptide specificity of CTL activity of the
HSC70 peptide-stimulated PBMCs against HLA-B46
þ tumour cells
was confirmed by means of competition assay. Namely, the CTL
activity against OSC20 cells was neutralised by the addition of
unlabelled EBV-B cells preloaded with the correspondent peptide
(HSC70106–114 in the upper right and HSC70233–241 peptide in the
lower right column), but not by those preloaded with a control
peptide (p53-derived peptide with HLA-B46-binding motif).
Representative results are shown in Figure 3B.
DISCUSSION
HSC70 is a highly conserved protein through various species; it is a
member of the family of molecular chaperones and plays an
important role in protein synthesis and folding, due to its ability to
prevent misfolding and aggregation and to promote folding and
translocation (Srivastava et al, 1998; Chen and Androlewicz, 2001;
Udono et al, 2001; Wang et al, 2002). Antigenic peptides are
usually generated by proteasomes and are translocated from the
cytoplasm to the endoplasmic reticulum by the transporter
associated with antigen processing. The chaperoned peptides can
be channelled into the endogenous class I presentation pathway of
a subset of professional antigen-presenting cells, which are then
able to prime CD8-positive CTLs. Further, purified preparations of
HSC70, gp96, HSP70, and calreticulin isolated from cancer cells
have been shown to elicit cancer-specific immunity against a wide
range of cancers in animal models (Tamura et al, 1997; Srivastava
et al, 1998; Dressel et al, 1999; Robert et al, 2001; Udono et al,
2001). In this study, we have reported for the first time that HSC70
gene encodes two nonmutated epitopes, at positions 106–114 and
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% specific lysis Figure 3 Inhibition tests and peptide specificity. (A) Inhibition test. IFN-g
production by the HSC70106–114 and HSC70233–241-stimulated PBMCs in
response to OSC20 tumour cells was tested at an E/T ratio of 20:1 in the
presence of 20mgml
 1 of anti-HLA class I, anti-HLA class II, anti-CD4, anti-
CD8, anti-CD14, or anti-HLA-B, C mAb. Values represent the means of
triplicate assays *Po0.05 by a two-tailed Student’s t-test. (B) Inhibition test
and peptide specificity. Cytotoxicity by the peptide-stimulated PBMCs
against OSC20 was tested at an E/T ratio of 20:1 in the presence of
20mgml
 1 of the mAb shown above. The CTL activity was inhibited by
anti-CD8, anti-HLA class I, and anti-HLA-B, C mAb, but not by any other
mAbs tested. For measurement of peptide specificity, an excess amount
(20mgml
 1) of a corresponding peptide (HSC70106–114 or HSC70233–241)
or a control peptide (p53204–212) was preloaded onto the
51Cr-labelled
OSC20 tumour cells, which were used as target cells in a 6-h
51Cr-release
assay. As cold cells, unlabelled EBV-B cells preloaded with either a
corresponding peptide (HSC70106–114 or HSC70233–241), or a control
peptide (p53204–212) were added to wells containing the
51Cr-labelled
OSC20 tumour cells, at a cold-to-hot cell ratio of 20:1. Values represent
the means of triplicate assays. *Po0.05 by a two-tailed Student’s t-test.
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reactive CTLs from PBMCs of the six of 10 epithelial cancer
patients tested. These findings suggest the two ways of HSC70
involvement in the immune response against tumour: the binding
and ‘carrying’ of antigenic peptides on the one hand and the
antigenic capacities of HSC70 by themselves on the other hand.
These results may facilitate the better understanding of molecular
mechanisms involved in tumour-derived HSC-70-mediated induc-
tion of specific immunity and CTL activation. However, it is not
clear yet whether HSC70 encodes antigenic peptides recognised by
HLA-A class I molecules since HLA-B4601 molecules are
exclusively expressed in Asians. It is also needed to investigate
whether the other chaperones such as HSP70 encode HLA-B46-
restricted CTL epitopes since three and one aa sequence of
HSC70106–114 and HSC70233–241 peptides differ from the corre-
sponding sequence of the HSP70, respectively. The other question
is the breaking of immunological tolerance against the autologous
HSC peptides. This question could partly be explained by the
overexpression of the HSC70 in tumour tissues shown in this
study. We reported that nonmutated self-antigens involved in
cellular proliferation and thus are highly expressed in tumour cells
such as SART1 and SART3 antigens often encode CTL epitope
peptides (Shichijo et al, 1998, Yang et al, 1999, Ito et al, 2001).
Although detailed mechanisms involved in these issues are not
clear at the present time, our results, along with those of previous
studies, suggest that the two HSC70-derived peptides are appro-
priate molecules in use for cancer vaccines to HLA-B46
þ epithelial
cancer patients.
Overexpression of the stress-inducible HSP70 has been shown in
various types of cancers (Ciocca et al, 1993; Kaur and Ralhan,
1995; Ralhan and Kaur, 1995; Ciocca et al, 1998; Jolly and
Morimoto, 2000; Zylicz et al, 2001) and are associated with poor
prognosis of cancer patients. We showed in this study by both
Northern and Western blot analyses that, not only the HSP70 but
also the constitutively expressed HSC70 was highly expressed in
epithelial cancer cell lines as compared to that of PBMCs. In
addition, the HSC70 had the ability to induce CTL responses
through binding and carrying antigenic peptides. The critical
region of HSC70 for binding and carrying antigenic peptides was
mapped to residues 280–385 in the ATPase domain (Udono et al,
2001), while the CTL epitopes were located at positions 106–114
and 233–241. Taken together, both the HSC70 and its peptides
might be an appropriate candidate in use for specific immu-
notherapy for cancer patients.
The HLA-B46 allele is expressed exclusively in Asians, but not in
other ethnic groups. This allele is expressed in 30% of Singapore
Chinese, 28% of the Thai population, 9% of Japanese, and 8% of
Koreans, whereas it is expressed in o1% of Caucasians, Blacks,
and Indians (Imanishi et al, 1992, Barber et al, 1996). We have
tested HLA-B expression at the serological level from 80 epithelial
cancer patients, including 10 colon cancer patients, but because of
its lower frequency in Japanese, PBMCs from only 10 HLA-B46
þ
cancer patients (five lung cancer and five prostate cancer patients)
and four HLA-B46
þ HD served as subjects for the CTL induction
assay. Owing to the limitation of available PBMCs for the study, the
experiments using these PBMCs were repeated twice in the
patients’ PBMCs and three times in the PBMCs from HDs.
Although the amounts of IFN-g produced by the peptide-
stimulated PBMCs were relatively low, this is in part due to the
small numbers of PBMCs used for the induction assay (10
5 cells
per well). Regardless of this limitation, however, all the data shown
in this study were consistent and reproducible. In particular, the
HLA-restricted cytotoxicity against tumour cells by means of the
51Cr-release assay was always obtained from the peptide-reactive
PBMCs from six cancer patients by means of IFN-g-release assay.
In contrast, the HLA-restricted cytotoxicity against tumour cells
was never obtained from the peptide-reactive PBMCs from two
HDs by means of IFN-g-release assay. Subsequently, CTL
precursors reacting to HSC70 peptides and tumour cells might
mainly be found in the circulation of substantial numbers of
cancer patients, while the CTLs to autologous HSC70 peptides are
under immunological tolerance in HDs. However, because of a
limited numbers of samples, further studies on HLA-B46
þ PBMCs
from colon cancer or the other types of cancers as well as PBMCs
from HDs are needed to confirm the results shown in this study.
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